| Literature DB >> 30573301 |
Julian Rydzek1, Thomas Nerreter1, Haiyong Peng2, Sabrina Jutz3, Judith Leitner3, Peter Steinberger3, Hermann Einsele1, Christoph Rader2, Michael Hudecek4.
Abstract
Chimeric antigen receptor (CAR)-T cell immunotherapy is under intense preclinical and clinical investigation, and it involves a rapidly increasing portfolio of novel target antigens and CAR designs. We established a platform that enables rapid and high-throughput CAR-screening campaigns with reporter cells derived from the T cell lymphoma line Jurkat. Reporter cells were equipped with nuclear factor κB (NF-κB) and nuclear factor of activated T cells (NFAT) reporter genes that generate a duplex output of enhanced CFP (ECFP) and EGFP, respectively. As a proof of concept, we modified reporter cells with CD19-specific and ROR1-specific CARs, and we detected high-level reporter signals that allowed distinguishing functional from non-functional CAR constructs. The reporter data were highly reproducible, and the time required for completing each testing campaign was substantially shorter with reporter cells (6 days) compared to primary CAR-T cells (21 days). We challenged the reporter platform to a large-scale screening campaign on a ROR1-CAR library, and we showed that reporter cells retrieved a functional CAR variant that was present with a frequency of only 6 in 1.05 × 106. The data illustrate the potential to implement this reporter platform into the preclinical development path of novel CAR-T cell products and to inform and accelerate the selection of lead CAR candidates for clinical translation.Entities:
Keywords: NF-κB/NFAT reporter cells; ROR1; cancer immunotherapy; chimeric antigen receptor; library screening
Mesh:
Substances:
Year: 2018 PMID: 30573301 PMCID: PMC6369451 DOI: 10.1016/j.ymthe.2018.11.015
Source DB: PubMed Journal: Mol Ther ISSN: 1525-0016 Impact factor: 11.454